MME and congestive heart failure: As a first‐line drug for the treatment of CHF patients, angiotensin receptor–neprilysin inhibitor (ARNI) can increase the concentration of natriuretic peptide (ANP) by inhibiting enkephalinase (NEP), which can play a greater diuretic effect than angiotensin‐converting enzyme inhibitor (ACEI)/angiotensin receptor blocker (ARB).